This study was an open evaluation of the efficacy and safety of Ketoco
nazole, 15 mg/kg/day orally for 3 weeks in 7 evaluable patients with V
isceral Leishmaniasis in Kenya, Of all the seven patients who received
ketoconazole, none had appreciable clearance of parasites from the sp
lenic aspirate smears that were microscopically examined, All the sple
nic aspirate cultures done on these patients in the three weeks remain
ed positive for leishmania parasites, Splenic sizes of these patients
generally remained unchanged throughout the study period, The mean hae
moglobin at the start of treatment was not different from that at the
end of treatment. Liver function tests throughout treatment remained u
nchanged, i.e. within normal limits. It is concluded that Ketoconazole
, 15 mg/kg/day orally given to these patients was not effective as an
antileishmania drug although there was a one log drop in the parasite
load. However, no serious side effect were noted in all of the patient
s during treatment.